Drug cocktail may cut transfusions for kids with thalassemia

NCT ID NCT06299670

Completed Disease control Sponsor: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether giving children with transfusion-dependent thalassemia a combination of hydroxyurea and thalidomide works better than either drug alone. Ninety children aged 3-18 were split into three groups: one getting both drugs, one getting only hydroxyurea, and one getting only thalidomide. Researchers measured changes in hemoglobin levels, transfusion frequency, and iron levels after three months to see which approach was most effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Hydroxyurea and Thalidomide
What this could lead to: If successful, this combination could reduce the need for blood transfusions in children with thalassemia, improving their quality of life.
What could go wrong: This is a small, single-center trial with only 90 participants. Results may not apply to all patients, and side effects from the drugs are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRANSFUSION-DEPENDENT THALASSEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

beta-thalassemia major

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRANSFUSION-DEPENDENT THALASSEMIA

Contacts and locations

Locations

Bangabandhu Sheikh Mujib Medical University

Dhaka, 1000, Bangladesh

More trials for these conditions

Other studies related to the condition(s) this trial covers.